The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study

Treatment with pembrolizumab, an anti-programmed cell death-1 (PDCD-1) monoclonal antibody for the treatment of non-small cell lung cancers (NSCLCs) requires prior immunohistochemical (IHC) analysis of the expression of the programmed death-ligand 1 (PD-L1) (also known as CD274 molecule) which is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Verocq, Camille, Decaestecker, Christine, Rocq, Laureen, De Clercq, Sarah, Verrellen, Audrey, Mekinda, Zita, Ocak, Sebahat, Compère, Christophe, Stanciu-Pop, Claudia, Salmon, Isabelle, Remmelink, Myriam, D'Haene, Nicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115063/
https://www.ncbi.nlm.nih.gov/pubmed/32269612
http://dx.doi.org/10.3892/ol.2020.11458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115063/
https://www.ncbi.nlm.nih.gov/pubmed/32269612
http://dx.doi.org/10.3892/ol.2020.11458

Ejemplares similares